<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39315108</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.</ArticleTitle><Pagination><StartPage>1448720</StartPage><MedlinePgn>1448720</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1448720</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1448720</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">When Coronavirus Disease-19 (COVID-19) struck the world in December 2019, initiatives started to investigate the efficacy of convalescent plasma, a readily available source of passive antibodies, collected from recovered patients as a therapeutic option. This was based on historical observational data from previous virus outbreaks.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A scoping review was conducted on the efficacy and safety of convalescent plasma and hyperimmune immunoglobulins for COVID-19 treatment. This review included the latest Cochrane systematic review update on 30-day mortality and safety. We also covered use in pediatric and immunocompromised patients, as well as the logistic challenges faced in donor recruitment and plasma collection in general. Challenges for low resource countries were specifically highlighted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A major challenge is the high donation frequency required from first-time donors to ensure a safe product, which minimizes the risk of transfusion-transmitted infectious. This is particularly difficult in low- and middle- income countries due to inadequate infrastructure and insufficient blood product supplies. High-certainty evidence indicates that convalescent plasma does not reduce mortality or significantly improve clinical outcomes in patients with moderate to severe COVID-19 infection. However, CCP may provide a viable treatment for patients unable to mount an endogenous immune response to SARS-CoV-2, based on mostly observational studies and subgroup data of published and ongoing randomized trials. Convalescent plasma has been shown to be safe in adults and children with COVID-19 infection. However, the efficacy in pediatric patients remains unclear.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Data on efficacy and safety of CCP are still underway in ongoing (randomized) studies and by reporting the challenges, limitations and successes encountered to-date, research gaps were identified to be addressed for the future.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This experience serves as a valuable example for future pandemic preparedness, particularly when therapeutic options are limited, and vaccines are either being developed or ineffective due to underlying immunosuppression.</AbstractText><CopyrightInformation>Copyright © 2024 So-Osman, Burnouf, Al-Riyami, Bloch, Estcourt, Goel, Tiberghien, Vermeulen, Wendel and Wood.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>So-Osman</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department Transfusion Medicine, Division Blood Bank, Sanquin Blood Supply Foundation, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Hematology, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnouf</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Riyami</LastName><ForeName>Arwa Z</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Evan M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estcourt</LastName><ForeName>Lise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Radcliffe Department of Medicine, University of Oxford and National Health Service (NHS) Blood and Transplant, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Ruchika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Simmons Cancer Institute at Southern Illinois University (SIU) School of Medicine, Springfield, IL, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept Corporate Medical Affairs, Vitalant Corporate Medical Affairs, Scottsdale, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Etablissement Français du Sang, La Plaine-St-Denis and Université de Franche-Comté, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeulen</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine and Technical Services, The South African National Blood Service, Roodepoort, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendel</LastName><ForeName>Silvano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept Transfusion Medicine, Hospital Sírio-Libanês Blood Bank, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">clinical use</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">plasma collection</Keyword><Keyword MajorTopicYN="N">scoping review</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39315108</ArticleId><ArticleId IdType="pmc">PMC11416983</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1448720</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. (2020) 579:270–3. doi: 10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. . Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfusion. (2016) 14:152. doi: 10.2450/2015.0131-15</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2015.0131-15</ArticleId><ArticleId IdType="pmc">PMC4781783</ArticleId><ArticleId IdType="pubmed">26674811</ArticleId></ArticleIdList></Reference><Reference><Citation>von Behring E, Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890. Mol Immunol. (1991) 28:1317, 1319–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">1749380</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon J. Emil Behring’s medical culture: from disinfection to serotherapy. Med history. (2007) 51:201–18. doi: 10.1017/S0025727300001198</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0025727300001198</ArticleId><ArticleId IdType="pmc">PMC1871706</ArticleId><ArticleId IdType="pubmed">17538695</ArticleId></ArticleIdList></Reference><Reference><Citation>Park WH. Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. J Am Med Assoc. (1932) 99:1050–3. doi: 10.1001/jama.1932.02740650008003</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1932.02740650008003</ArticleId></ArticleIdList></Reference><Reference><Citation>Park WH, Freeman RG. The prophylactic use of measles convalescent serum. J Am Med Assoc. (1926) 87:556–8. doi: 10.1001/jama.1926.02680080022009</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1926.02680080022009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health Nations Health. (1935) 25:595–8. doi: 10.2105/AJPH.25.5.595</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.25.5.595</ArticleId><ArticleId IdType="pmc">PMC1559172</ArticleId><ArticleId IdType="pubmed">18014217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambar AC. Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Children. (1946) 71:1–13. doi: 10.1001/archpedi.1946.02020240008001</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.1946.02020240008001</ArticleId><ArticleId IdType="pubmed">21018124</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. (2010) 38:e66–73. doi: 10.1097/CCM.0b013e3181d44c1e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181d44c1e</ArticleId><ArticleId IdType="pubmed">20154602</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis F, Hall M, Gaines A. Early use of convalescent serum in influenza. Mil Surg. (1920) 47:177–9.</Citation></Reference><Reference><Citation>Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med. (1919) 27:181–2.</Citation></Reference><Reference><Citation>Miller O, McConnell W. Report of influenza treated with serum from recovered cases. Ky Med J. (1919) 17:218–9.</Citation></Reference><Reference><Citation>Redden WR. Treatment of influenza-pneumonia by use of convalescent human serum. Boston Med Surg J. (1919) 181:688–91. doi: 10.1056/NEJM191912111812406</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM191912111812406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd LE, Follmann D, Proschan M, Wang J, Malvy D, van Griensven J, et al. . A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Sci Trans Med. (2019) 11:1–10. doi: 10.1126/scitranslmed.aaw1049</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaw1049</ArticleId><ArticleId IdType="pubmed">31776287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. (2015) 211:80–90. doi: 10.1093/infdis/jiu396</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu396</ArticleId><ArticleId IdType="pmc">PMC4264590</ArticleId><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. (2011) 52:447–56. doi: 10.1093/cid/ciq106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq106</ArticleId><ArticleId IdType="pmc">PMC7531589</ArticleId><ArticleId IdType="pubmed">21248066</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. (2005) 24:44–6. doi: 10.1007/s10096-004-1271-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-004-1271-9</ArticleId><ArticleId IdType="pmc">PMC7088355</ArticleId><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo Y, Cheng Y, Wong R, Hui D, Lee C, Tsang K, et al. . Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol infection. (2004) 10:676–8. doi: 10.1111/j.1469-0691.2004.00956.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2004.00956.x</ArticleId><ArticleId IdType="pmc">PMC7129386</ArticleId><ArticleId IdType="pubmed">15214887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong V, Dai D, Wu A, Sung J. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. (2003) 9:199–201.</Citation><ArticleIdList><ArticleId IdType="pubmed">12777656</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh K-M, Chiueh T-S, Siu L, Lin J-C, Chan PK, Peng M-Y, et al. . Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrobial Chemother. (2005) 56:919–22. doi: 10.1093/jac/dki346</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki346</ArticleId><ArticleId IdType="pmc">PMC7110092</ArticleId><ArticleId IdType="pubmed">16183666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz JR, Rudd KE, Clark DV, Jacob ST, West TE. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Crit Care Med. (2013) 41:1345–52. doi: 10.1097/CCM.0b013e3182771386</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182771386</ArticleId><ArticleId IdType="pubmed">23399939</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. (1979) 2:1216–7. doi: 10.1016/s0140-6736(79)92335-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(79)92335-3</ArticleId><ArticleId IdType="pubmed">92624</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. (2020) 323:1561–2. doi: 10.1001/jama.2020.4940</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4940</ArticleId><ArticleId IdType="pubmed">32219429</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. (2006) 145:599–609. doi: 10.7326/0003-4819-145-8-200610170-00139</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-145-8-200610170-00139</ArticleId><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, et al. . Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. (2017) 5:500–11. doi: 10.1016/s2213-2600(17)30174-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(17)30174-1</ArticleId><ArticleId IdType="pmc">PMC5828518</ArticleId><ArticleId IdType="pubmed">28522352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. (2020) 395:565–74. doi: 10.1016/S0140-6736(20)30251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-coV-2 is essential for infection of human lung cells. Mol Cell. (2020) 78:779–784 e5. doi: 10.1016/j.molcel.2020.04.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.04.022</ArticleId><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. . SARS-coV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181(2):271–80. doi: 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Smith DM. SARS-coV-2 variants of concern. Yonsei Med J. (2021) 62:961–8. doi: 10.3349/ymj.2021.62.11.961</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2021.62.11.961</ArticleId><ArticleId IdType="pmc">PMC8542474</ArticleId><ArticleId IdType="pubmed">34672129</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves DC, Rowland-Jones SL, Angyal A. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochem Biophys Res Commun. (2021) 538:104–7. doi: 10.1016/j.bbrc.2020.10.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.109</ArticleId><ArticleId IdType="pmc">PMC7643658</ArticleId><ArticleId IdType="pubmed">33199022</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer EM, Babiker A, Adelman MW, Allman B, Key A, Kleinhenz JM, et al. . SARS-coV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. (2022) 386:2436–8. doi: 10.1056/NEJMc2202861</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202861</ArticleId><ArticleId IdType="pmc">PMC9202319</ArticleId><ArticleId IdType="pubmed">35675197</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. (2021) 372:1–9. doi: 10.1126/science.abg3055</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabino EC, Buss LF, Carvalho MPS, Prete CA, Jr., Crispim MAE, Fraiji NA, et al. . Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. (2021) 397:452–5. doi: 10.1016/S0140-6736(21)00183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00183-5</ArticleId><ArticleId IdType="pmc">PMC7906746</ArticleId><ArticleId IdType="pubmed">33515491</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. . Deep mutational scanning of SARS-coV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. (2020) 182:1295–1310 e20. doi: 10.1016/j.cell.2020.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. (2021) 27:622–5. doi: 10.1038/s41591-021-01285-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. . Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. (2021) 593:142–6. doi: 10.1038/s41586-021-03471-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03471-w</ArticleId><ArticleId IdType="pmc">PMC9867906</ArticleId><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. (2021) 596:276–80. doi: 10.1038/s41586-021-03777-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. (2022) 376:eabn4947. doi: 10.1126/science.abn4947</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn4947</ArticleId><ArticleId IdType="pmc">PMC8995029</ArticleId><ArticleId IdType="pubmed">35289632</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC tracks new SARS-coV-2 variant, BA.2.87.1 (2024). Available online at: https://www.cdc.gov/ncird/whats-new/covid-19-variant-update-2024-02-09.html (Accessed February 24, 2024).</Citation></Reference><Reference><Citation>Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. . Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. (2022) 602:676–81. doi: 10.1038/s41586-021-04388-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. . The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. (2022) 11:1–5. doi: 10.1080/22221751.2021.2017757</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2017757</ArticleId><ArticleId IdType="pmc">PMC8725892</ArticleId><ArticleId IdType="pubmed">34890524</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Hong W, Lei H, He C, Lei W, Zhou Y, et al. . Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection. Signal Transduct Target Ther. (2023) 8:252. doi: 10.1038/s41392-023-01495-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01495-4</ArticleId><ArticleId IdType="pmc">PMC10279763</ArticleId><ArticleId IdType="pubmed">37336889</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallian P, Brisbarre N, Nurtop E, Le Cam S, Franck T, Isnard C, et al. . Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1. Vox Sang. (2023) 118:407–8. doi: 10.1111/vox.13418</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13418</ArticleId><ArticleId IdType="pubmed">36897221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Evans DH, Robbins NF, Orjuela G, Abe KT, Rathod B, et al. . Diminished neutralization capacity of SARS-coV-2 omicron BA.1 in donor plasma collected from January to March 2021. Microbiol Spectr. (2023) 11:e0525622. doi: 10.1128/spectrum.05256-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.05256-22</ArticleId><ArticleId IdType="pmc">PMC10434250</ArticleId><ArticleId IdType="pubmed">37289096</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Riyami AZ, Burnouf T, Wood EM, Devine DV, Oreh A, Apelseth TO, et al. . International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. Vox Sang. (2022) 117:822–30. doi: 10.1111/vox.13256</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13256</ArticleId><ArticleId IdType="pmc">PMC9115426</ArticleId><ArticleId IdType="pubmed">35262978</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. (2020) 115:485–7. doi: 10.1111/vox.12939</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12939</ArticleId><ArticleId IdType="pmc">PMC7264781</ArticleId><ArticleId IdType="pubmed">32319102</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhai A, Wu AA, Hall L, Strauss D, Paradiso S, Alberigo J, et al. . How did we rapidly implement a convalescent plasma program? Transfusion. (2020) 60:1348–55. doi: 10.1111/trf.15910</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15910</ArticleId><ArticleId IdType="pmc">PMC7283779</ArticleId><ArticleId IdType="pubmed">32449169</ArticleId></ArticleIdList></Reference><Reference><Citation>
An EU programme of COVID-19 convalescent plasma collection and transfusion Guidance on collection, testing, processing, storage, distribution and monitored use (2021). Available online at: https://health.ec.europa.eu/system/files/2021-03/guidance_plasma_covid19_en_0.pdf (Accessed June 3, 2022).</Citation></Reference><Reference><Citation>Wendel S, Land K, Devine DV, Daly J, Bazin R, Tiberghien P, et al. . Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. Vox Sang. (2021) 116(8):872–9. doi: 10.1111/vox.13096</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13096</ArticleId><ArticleId IdType="pmc">PMC8250874</ArticleId><ArticleId IdType="pubmed">33772791</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. (2020) 584:437–42. doi: 10.1038/s41586-020-2456-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd RY, t. Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. (2002) 42:975–9. doi: 10.1046/j.1537-2995.2002.00174.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.2002.00174.x</ArticleId><ArticleId IdType="pubmed">12385406</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappy P, Candotti D, Sauvage V, Lucas Q, Boizeau L, Gomez J, et al. . No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation. Blood. (2020) 136:1888–91. doi: 10.1182/blood.2020008230</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008230</ArticleId><ArticleId IdType="pmc">PMC7568032</ArticleId><ArticleId IdType="pubmed">32871595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindawi S, Elgemmezi T, El-Kafrawy SA, Samadani H, Tilmisani M, Assiri O, et al. . Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma. Transfus Apher Sci. (2023) 62:103688. doi: 10.1016/j.transci.2023.103688</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2023.103688</ArticleId><ArticleId IdType="pmc">PMC9984302</ArticleId><ArticleId IdType="pubmed">36922242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D, Casadevall A. COVID-19 serology data provide guidance for future deployments of convalescent plasma. mBio. (2023) 14:e0042823. doi: 10.1128/mbio.00428-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00428-23</ArticleId><ArticleId IdType="pmc">PMC10294630</ArticleId><ArticleId IdType="pubmed">37039667</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA . FDA Guidance of Tests Acceptable for Use in the Manufacture of COVID-19 Convalescent Plasma with High Titers of Anti-SARS-CoV-2 Antibodies. (2021). Available online at: https://www.fda.gov/search?s=FDA.+FDA+Guidance+of+Tests+Acceptable+for+Use+in+the+Manufacture+of+COVID-19+Convalescent+Plasma+with+High+Titers+of+Anti-SARS-CoV-2+Antibodies.+2021 (Accessed March 23, 2022).</Citation></Reference><Reference><Citation>Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. . Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. (2020) 130:6141–50. doi: 10.1172/JCI142004</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI142004</ArticleId><ArticleId IdType="pmc">PMC7598041</ArticleId><ArticleId IdType="pubmed">32764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel A, Hoffmann S, Jahrsdorfer B, Korper S, Ludwig C, Vieweg C, et al. . SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Front Immunol. (2023) 14:1170759. doi: 10.3389/fimmu.2023.1170759</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1170759</ArticleId><ArticleId IdType="pmc">PMC10166809</ArticleId><ArticleId IdType="pubmed">37180152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurmi V, Knight C, Estcourt L, Hepojoki J, Lamikanra AA, Tsang HP, et al. . The relationship between SARS-coV-2 neutralizing antibody titers and avidity in plasma collected from convalescent nonvaccinated and vaccinated blood donors. J Infect Dis. (2023) 228:245–50. doi: 10.1093/infdis/jiad070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad070</ArticleId><ArticleId IdType="pmc">PMC10420400</ArticleId><ArticleId IdType="pubmed">36967714</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Peng L, Zheng L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. . Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants. Heliyon. (2024) 10:e27033. doi: 10.1016/j.heliyon.2024.e27033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e27033</ArticleId><ArticleId IdType="pmc">PMC10938114</ArticleId><ArticleId IdType="pubmed">38486776</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodhue Meyer E, Simmons G, Grebe E, Gannett M, Franz S, Darst O, et al. . Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay. Transfusion. (2021) 61(4):1160–70. doi: 10.1111/trf.16321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16321</ArticleId><ArticleId IdType="pmc">PMC8013397</ArticleId><ArticleId IdType="pubmed">33554362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel S, Fachini R, Fontao-Wendel RCL, Mello R, Velasquez CV, MaChado RRG, et al. . Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be? Transfusion. (2021) 61:3455–67. doi: 10.1111/trf.16714</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16714</ArticleId><ArticleId IdType="pmc">PMC8661940</ArticleId><ArticleId IdType="pubmed">34674284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Ma P, Orzechowski M, Lemmer A, Rzasa K, Bagnall J, et al. . High-throughput neutralization and serology assays reveal correlated but highly variable humoral immune responses in a large population of individuals infected with SARS-coV-2 in the US between March and August 2020. mBio. (2023) 14:e0352322. doi: 10.1128/mbio.03523-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03523-22</ArticleId><ArticleId IdType="pmc">PMC10128039</ArticleId><ArticleId IdType="pubmed">36786604</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnouf T, Gathof B, Bloch EM, Bazin R, de Angelis V, Patidar GK, et al. . Production and quality assurance of human polyclonal hyperimmune immunoglobulins against SARS-coV-2. Transfusion Med Rev. (2022) 36(3):125–32. doi: 10.1016/j.tmrv.2022.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2022.06.001</ArticleId><ArticleId IdType="pmc">PMC9183240</ArticleId><ArticleId IdType="pubmed">35879213</ArticleId></ArticleIdList></Reference><Reference><Citation>Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. (2010) 98:12–28. doi: 10.1111/j.1423-0410.2009.01226.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2009.01226.x</ArticleId><ArticleId IdType="pubmed">19660029</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandeberg P, Cruz M, Diez JM, Merritt WK, Santos B, Trukawinski S, et al. . Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Transfusion. (2021) 61:1705–9. doi: 10.1111/trf.16378</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16378</ArticleId><ArticleId IdType="pmc">PMC8251388</ArticleId><ArticleId IdType="pubmed">33715160</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, et al. . Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Systematic Rev. (2023). doi: 10.1002/14651858.CD013600.pub6</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013600.pub6</ArticleId><ArticleId IdType="pmc">PMC9891348</ArticleId><ArticleId IdType="pubmed">36734509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. . SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Systematic Rev. (2021) 9). doi: 10.1002/14651858.CD013825.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013825.pub2</ArticleId><ArticleId IdType="pmc">PMC8411904</ArticleId><ArticleId IdType="pubmed">34473343</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. . Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. (2021) 384:610–8. doi: 10.1056/NEJMoa2033700</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. . Early outpatient treatment for covid-19 with convalescent plasma. N Engl J Med. (2022) 386:1700–11. doi: 10.1056/NEJMoa2119657</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119657</ArticleId><ArticleId IdType="pmc">PMC9006786</ArticleId><ArticleId IdType="pubmed">35353960</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, et al. . Transfusing convalescent plasma as post-exposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) infection: A double-blinded, phase 2 randomized, controlled trial. Clin Infect Dis. (2023) 76:e477–86. doi: 10.1093/cid/ciac372</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac372</ArticleId><ArticleId IdType="pmc">PMC9129191</ArticleId><ArticleId IdType="pubmed">35579509</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the REMAP-CAP Investigators. Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, et al. . Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA. (2021) 326:1690–702. doi: 10.1001/jama.2021.18178</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.18178</ArticleId><ArticleId IdType="pmc">PMC8491132</ArticleId><ArticleId IdType="pubmed">34606578</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemany A, Millat-Martinez P, Corbacho-Monne M, Malchair P, Ouchi D, Ruiz-Comellas A, et al. . High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. (2022) 10:278–88. doi: 10.1016/S2213-2600(21)00545-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00545-2</ArticleId><ArticleId IdType="pmc">PMC8828369</ArticleId><ArticleId IdType="pubmed">35150610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, Baumgart A, Evangelidis N, Viecelli AK, Carter SA, Azevedo LC, et al. . Core outcome measures for trials in people with coronavirus disease 2019: respiratory failure, multiorgan failure, shortness of breath, and recovery. Crit Care Med. (2021) 49:503–16. doi: 10.1097/CCM.0000000000004817</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004817</ArticleId><ArticleId IdType="pmc">PMC7892260</ArticleId><ArticleId IdType="pubmed">33400475</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. . Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. (2020) 95:1888–97. doi: 10.1016/j.mayocp.2020.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.06.028</ArticleId><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>
ISBT Proposed standard definitions for surveillance of non-infectious adverse transfusion reactions (2011). Available online at: https://www.isbtweb.org/resource/en-2011-isbt-proposed-standard-definitions-for-surveillance-of-non-infectious-adverse-transfusion-reactions.html (Accessed June 7, 2024).</Citation></Reference><Reference><Citation>
AABB-quick-reference-guide-nhsn-hemovigilance-module. Available online at: https://www.aabb.org/docs/default-source/default-document-library/resources/aabb-quick-reference-guide-nhsn-hemovigilance-module.pdf?sfvrsn=30f1600b_4 (Accessed June 7, 2024).</Citation></Reference><Reference><Citation>Leblanc JF, Germain M, Delage G, O’Brien S, Drews SJ, Lewin A. Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review. Transfusion. (2020) 60:3046–54. doi: 10.1111/trf.16056</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16056</ArticleId><ArticleId IdType="pmc">PMC7461295</ArticleId><ArticleId IdType="pubmed">32798237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacombe K, Hueso T, Porcher R, Mekinian A, Chiarabini T, Georgin-Lavialle S, et al. . Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomized clinical trial. BMJ Med. (2023) 2:e000427. doi: 10.1136/bmjmed-2022-00042</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-00042</ArticleId><ArticleId IdType="pmc">PMC10619082</ArticleId><ArticleId IdType="pubmed">37920150</ArticleId></ArticleIdList></Reference><Reference><Citation>Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, de Molina RM, Torres F, et al. . A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. (2021) 131:p1–10. doi: 10.1172/JCI152740</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI152740</ArticleId><ArticleId IdType="pmc">PMC8516461</ArticleId><ArticleId IdType="pubmed">34473652</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo A, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. . FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. (2022) 606:576–84. doi: 10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, et al. . Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. (2022) 606:585–93. doi: 10.1038/s41586-022-04802-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll TD, Wong T, Morris MK, Di Germanio C, Ma ZM, Stone M, et al. . Vaccine-boosted CCP decreases virus replication and hastens resolution of infection despite transiently enhancing disease in SARS-coV-2-infected hamsters. J Infect Dis. (2024) 229(6):1702–10. doi: 10.1093/infdis/jiad568</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad568</ArticleId><ArticleId IdType="pmc">PMC11175670</ArticleId><ArticleId IdType="pubmed">38213276</ArticleId></ArticleIdList></Reference><Reference><Citation>Group IS. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet. (2022) 399:530–40. doi: 10.1016/S0140-6736(22)00101-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00101-5</ArticleId><ArticleId IdType="pmc">PMC8797010</ArticleId><ArticleId IdType="pubmed">35093205</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. . Antibody response to 2-dose SARS-coV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. (2021) 325:2204–6. doi: 10.1001/jama.2021.7489</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7489</ArticleId><ArticleId IdType="pmc">PMC8100911</ArticleId><ArticleId IdType="pubmed">33950155</ArticleId></ArticleIdList></Reference><Reference><Citation>Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. (2020) 5:CD013600. doi: 10.1002/14651858.CD013600</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013600</ArticleId><ArticleId IdType="pmc">PMC7271896</ArticleId><ArticleId IdType="pubmed">32406927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, et al. . A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. (2021) 131. doi: 10.1172/JCI155114</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI155114</ArticleId><ArticleId IdType="pmc">PMC8670841</ArticleId><ArticleId IdType="pubmed">34788233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. . SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Systematic Rev. (2022) 6). doi: 10.1002/14651858.CD014945.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD014945.pub2</ArticleId><ArticleId IdType="pmc">PMC9205158</ArticleId><ArticleId IdType="pubmed">35713300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, et al. . Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. (2021) 12:3189. doi: 10.1038/s41467-021-23469-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23469-2</ArticleId><ArticleId IdType="pmc">PMC8160346</ArticleId><ArticleId IdType="pubmed">34045486</ArticleId></ArticleIdList></Reference><Reference><Citation>
Expert panel updates guidelines for clinical CCP use (2022). Available online at: https://www.aabb.org/news-resources/news/article/2022/04/13/aabb-expert-panel-updates-guidelines-for-clinical-ccp-use (Accessed July 27, 2022).</Citation></Reference><Reference><Citation>Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. . Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. (2021) 7:1167–75. doi: 10.1001/jamaoncol.2021.1799</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.1799</ArticleId><ArticleId IdType="pmc">PMC8377563</ArticleId><ArticleId IdType="pubmed">34137799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Godron A-S, Lanoy E, Pacanowski J, Levi LI, Gras E, et al. . Convalescent plasma improves overall survival in patients with B-cell lymphoid Malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia. (2022) 36:1025–34. doi: 10.1038/s41375-022-01511-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01511-6</ArticleId><ArticleId IdType="pmc">PMC8805670</ArticleId><ArticleId IdType="pubmed">35105946</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. . mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. (2021) 372(6549):1413–8. doi: 10.1126/science.abg9175</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg9175</ArticleId><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel A, Jahrsdörfer B, Körper S, Albers D, von Maltitz P, Müller R, et al. . SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays. medRxiv. (2022), p1–21. doi: 10.1101/2022.01.17.22269201</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.17.22269201</ArticleId><ArticleId IdType="pmc">PMC10166809</ArticleId><ArticleId IdType="pubmed">37180152</ArticleId></ArticleIdList></Reference><Reference><Citation>Parri N, Lenge M, Buonsenso D, G. Coronavirus Infection in Pediatric Emergency Departments Research . Children with covid-19 in pediatric emergency departments in Italy. N Engl J Med. (2020) 383(2):187–90. doi: 10.1056/NEJMc2007617</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007617</ArticleId><ArticleId IdType="pmc">PMC7206930</ArticleId><ArticleId IdType="pubmed">32356945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, et al. . A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. BMC Med. (2020) 18:123. doi: 10.1186/s12916-020-01596-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01596-9</ArticleId><ArticleId IdType="pmc">PMC7200209</ArticleId><ArticleId IdType="pubmed">32370747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaffanello M, Piacentini G, Nosetti L, Franchini M. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review. Transfus Apher Sci. (2021) 60:103043. doi: 10.1016/j.transci.2020.103043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.103043</ArticleId><ArticleId IdType="pmc">PMC7834628</ArticleId><ArticleId IdType="pubmed">33388249</ArticleId></ArticleIdList></Reference><Reference><Citation>Małecki P, Faltin K, Mania A, Mazur-Melewska K, Cwalińska A, Zawadzka A, et al. . Effects and safety of convalescent plasma administration in a group of polish pediatric patients with COVID-19: A case series. Life (Basel). (2021) 11:p1–10. doi: 10.3390/life11030247</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11030247</ArticleId><ArticleId IdType="pmc">PMC8002380</ArticleId><ArticleId IdType="pubmed">33802763</ArticleId></ArticleIdList></Reference><Reference><Citation>
National COVID-19 Convalescent Plasma Project; Protocols for Pediatrics (2020). Available online at: https://ccpp19.org/healthcare_providers/component_3/protocols_for_pediatrics.html (Accessed July 27th 2022).</Citation></Reference><Reference><Citation>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. (2021) 397:2049–59. doi: 10.1016/s0140-6736(21)00897-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00897-7</ArticleId><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon O, Brosnan MK, Yoon S, Jung D, Littlefield K, Ganesan A, et al. . Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight. (2021) 7(2):e151518. doi: 10.1172/jci.insight.151518</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151518</ArticleId><ArticleId IdType="pmc">PMC8855821</ArticleId><ArticleId IdType="pubmed">34855624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai H, Ji Y, Wang J, Zhang X. Efficacy of human coronavirus immune convalescent plasma for the treatment of corona virus disease -19 disease in hospitalized children: A protocol for systematic review and meta analysis. Medicine (Baltimore) (2020) 99(45):e22017. doi: 10.1097/MD.0000000000022017</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000022017</ArticleId><ArticleId IdType="pmc">PMC7647599</ArticleId><ArticleId IdType="pubmed">33157910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquot C, Gordon O, Noland D, Donowitz JR, Levy E, Jain S, et al. . Multi-institutional experience with COVID-19 convalescent plasma in children. Transfusion. (2023) 63:918–24. doi: 10.1111/trf.17318</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17318</ArticleId><ArticleId IdType="pmc">PMC10175190</ArticleId><ArticleId IdType="pubmed">36965173</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrieta A, Galvis AE, Osborne S, Morphew T, Imfeld K, Enriquez C, et al. . Use of COVID-19 convalescent plasma for treatment of symptomatic SARS-coV-2 infection at a children’s hospital: A contribution to a still inadequate body of evidence. Children (Basel). (2023) 10:p1–12. doi: 10.3390/children10020350</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children10020350</ArticleId><ArticleId IdType="pmc">PMC9955755</ArticleId><ArticleId IdType="pubmed">36832478</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein J, Smid WM, Wendel S, Somuah D, Burnouf T. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. Vox Sang. (2020) 116(1):13–14. doi: 10.1111/vox.12964</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12964</ArticleId><ArticleId IdType="pmc">PMC7283681</ArticleId><ArticleId IdType="pubmed">32464700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Goel R, Wendel S, Burnouf T, Al-Riyami AZ, Ang AL, et al. . Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. Vox Sang. (2020) 116(1):18–35. doi: 10.1111/vox.12970</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12970</ArticleId><ArticleId IdType="pmc">PMC7323328</ArticleId><ArticleId IdType="pubmed">32533868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Goel R, Montemayor C, Cohn C, Tobian AAR. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. Vox Sang. (2021) 116(1):18–35. doi: 10.1016/j.transci.2020.102957</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102957</ArticleId><ArticleId IdType="pmc">PMC7502258</ArticleId><ArticleId IdType="pubmed">32972861</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts N, James S, Delaney M, Fitzmaurice C. The global need and availability of blood products: a modelling study. Lancet Haematol. (2019) 6:e606–15. doi: 10.1016/S2352-3026(19)30200-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30200-5</ArticleId><ArticleId IdType="pubmed">31631023</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimer A, Tagny CT, Tapko JB, Gouws C, Tobian AAR, Ness PM, et al. . Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century. Transfusion. (2019) 59:412–27. doi: 10.1111/trf.14949</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14949</ArticleId><ArticleId IdType="pubmed">30615810</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. (2019) 133:1854–64. doi: 10.1182/blood-2018-11-833996</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-833996</ArticleId><ArticleId IdType="pubmed">30808637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev. (2012) 26:164–80. doi: 10.1016/j.tmrv.2011.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2011.07.006</ArticleId><ArticleId IdType="pmc">PMC3668661</ArticleId><ArticleId IdType="pubmed">21872426</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, et al. . Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PloS Med. (2021) 18:e1003872. doi: 10.1371/journal.pmed.1003872</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003872</ArticleId><ArticleId IdType="pmc">PMC8730442</ArticleId><ArticleId IdType="pubmed">34928960</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. . Convalescent plasma antibody levels and the risk of death from covid-19. New Engl J Med. (2021) 384:1015–27. doi: 10.1056/NEJMoa2031893</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031893</ArticleId><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch EM, Tobian AAR, Shoham S, Hanley DF, Gniadek TJ, Cachay ER, et al. . How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. (2022) 62:933–41. doi: 10.1111/trf.16871</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16871</ArticleId><ArticleId IdType="pmc">PMC9086144</ArticleId><ArticleId IdType="pubmed">35352362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson ML, Fleming KA, Kuti MA, Looi LM, Lago N, Ru K. Access to pathology and laboratory medicine services: a crucial gap. Lancet. (2018) 391:1927–38. doi: 10.1016/S0140-6736(18)30458-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30458-6</ArticleId><ArticleId IdType="pubmed">29550029</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Franchini M, Maggi F. Modified hemagglutination tests for COVID-19 serology in resource-poor settings: ready for prime-time? Vaccines (Basel). (2022) 10:1–6. doi: 10.3390/vaccines10030406</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030406</ArticleId><ArticleId IdType="pmc">PMC8953758</ArticleId><ArticleId IdType="pubmed">35335038</ArticleId></ArticleIdList></Reference><Reference><Citation>A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. (2020) 20:e192–7. doi: 10.1016/s1473-3099(20)30483-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, et al. . COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. (2022. 35(3)):e0020021. doi: 10.1128/cmr.00200-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00200-21</ArticleId><ArticleId IdType="pmc">PMC9491201</ArticleId><ArticleId IdType="pubmed">35262370</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio. (2021) 12:1–13. doi: 10.1128/mBio.03372-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.03372-20</ArticleId><ArticleId IdType="pmc">PMC8092292</ArticleId><ArticleId IdType="pubmed">33653885</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. . Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results. N Engl J Med. (2021) 384:497–511. doi: 10.1056/NEJMoa2023184</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Axfors C, Janiaud P, Schmitt AM, Van’t Hooft J, Smith ER, Haber NA, et al. . Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. (2021) 21:1170. doi: 10.1186/s12879-021-06829-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06829-7</ArticleId><ArticleId IdType="pmc">PMC8605464</ArticleId><ArticleId IdType="pubmed">34800996</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA . Regulatory Update: FDA Issues Revised CCP Guidance, AABB Updates CCP
Toolkit. (2021). Available online at: https://www.aabb.org/news-resources/news/article/2022/01/11/regulatory-update-fda-issuesrevised-ccp-guidance-aabb-updates-ccp-toolkit (Accessed July 27th 2022).</Citation></Reference><Reference><Citation>Al-Riyami AZ, Schäfer R, van den Berg K, Bloch EM, Estcourt LJ, Goel R, et al. . Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sang. (2021) 116:88–98. doi: 10.1111/vox.12973</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12973</ArticleId><ArticleId IdType="pmc">PMC7891452</ArticleId><ArticleId IdType="pubmed">32542847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann J, Bloch EM, Burnouf T. Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. Transfusion. (2022) 62:681–4. doi: 10.1111/trf.16810</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16810</ArticleId><ArticleId IdType="pubmed">35098540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood EM, Estcourt LJ, McQuilten ZK. How should we use convalescent plasma therapies for the management of COVID-19? Blood. (2021) 137:1573–81. doi: 10.1182/blood.2020008903</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008903</ArticleId><ArticleId IdType="pmc">PMC7992504</ArticleId><ArticleId IdType="pubmed">33202419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>